natgillin/translations-raw huggingface dataset:
Very rare Tendon pain, headache, visual abnormalities, 
Bolezni živčevja zelo redki bolečina v kitah, glavobol, nepravilnosti vida, periferna nevropatija, omotica pogosti vrtoglavica, vestibularni sindrom
Dibutyl sebacate 
Okvara jeter
GRANUPAS 4 g gastro-resistant granules para-aminosalicylic acid 
GRANUPAS 4 g gastrorezistentna zrnca para-aminosalicilna kislina
See section 4.2 for posology adjustments for desensitization. 
Za navodila o tem, kako prilagajati odmerjanje za desenzibilizacijo, glejte poglavje 4.2.
This medicine is presented as light brown gastro-resistant granules in sachets. 
Izgled zdravila GRANUPAS in vsebina pakiranja Zdravilo je v obliki svetlorjavih gastrorezistentnih zrnc v vrečicah.
• giddiness, 
• driska,
• stomach ache (abdominal pain), 
• bolečina v želodcu (bolečina v trebuhu),
• visual abnormalities, 
• nepravilnosti vida,
Package leaflet: Information for the patient GRANUPAS 4 g gastro-resistant granules para-aminosalicylic acid 
Navodilo za uporabo GRANUPAS 4 g gastrorezistentna zrnca para-aminosalicilna kislina
Methacrylic acid - Ethyl acrylate copolymer (1:1) Dispersion 30 per cent Hypromellose 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi koloidni hidratirani silicijev dioksid dibutilsebakat metakrilna kislina in etilakrilat, kopolimer 1 : 1, 30-odstotna disperzija hipromeloza mikrokristalna celuloza smukec
Hepatic impairment 
Želodčna razjeda
• nausea, 
• bruhanje,
• vomiting, 
• napihnjenost,
Common abdominal pain, vomiting, nausea, bloating, diarrhea, soft stools. 
Bolezni prebavil pogosti bolečina v trebuhu, bruhanje, navzea, napihnjenost, driska, mehko blato občasni anoreksija redki malabsorpcijski sindrom*, želodčna razjeda,
Increased blood alkaline phosphatase, transaminases, weight loss. 
Preiskave zelo redki zmanjšana koncentracija protrombina, jetrna citoliza, zvišane ravni alkalne fosfataze in transaminaz v krvi, zmanjšanje telesne mase
Medical Need Europe AB Puh/Tel: + 46 8 533 39 500 info@medicalneed.com 
Suomi/Finland Medical Need Europe AB Puh/Tel: + 46 8 533 39 500
Deutschland 
Francija
Skin and subcutaneous tissue disorders 
Bolezni jeter, žolčnika in žolčevodov neznana hepatitis
GRANUPAS 4g gastro-resistant granules para aminosalicylic acid Oral use 
GRANUPAS 4 g gastrorezistentna zrnca para-aminosalicilna kislina peroralna uporaba
Eurocept International BV (Lucane Pharma) Trapgans 5 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Eurocept International BV (Lucane Pharma)
However, para-aminosalicylic acid appears to be a weak inhibitor of DHP in vitro, raising the possibility that it may have a different target. 
Vendar pa kaže, da je para-aminosalicilna kislina in vitro šibek zaviralec
• dizziness, 
• razjeda,
Talk to your doctor or pharmacist before taking GRANUPAS 
Pred začetkom jemanja zdravila GRANUPAS se posvetujte z zdravnikom ali farmacevtom:
Contents of the pack and other information What GRANUPAS contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo GRANUPAS Zdravilna učinkovina je para-aminosalicilna kislina.
• reduction in blood platelets, 
• zmanjšana koncentracija trombocitov v krvi,
Medical Need Europe AB Tlf: + 46 8 533 39 500 info@medicalneed.com 
Medical Need Europe AB Tlf: + 46 8 533 39 500
What GRANUPAS is and what it is used for What you need to know before you take GRANUPAS How to take GRANUPAS 
Kaj morate vedeti, preden boste vzeli zdravilo GRANUPAS
Common Cutaneous hypersensitivity, skin rash. 
Bolezni kože in podkožja pogosti preobčutljivostna kožna reakcija, kožni izpuščaj redki urtikarija
Medical Need Europe AB Tel: + 46 8 533 39 500 info@medicalneed.com 
Medical Need Europe AB Tel: + 46 8 533 39 500
28 pessaries + 6 applicators 
28 vaginalnih globul + 6 aplikatorjev
Vaginal use blister (PVC/PE) 
Vaginalna uporaba pretisni omot (PVC/PE)
Intrarosa 
Jakost
Immediate Packaging 
Primarna ovojnina Velikost pakiranja
The full EPAR for Pantoloc Control can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Pantoloc Control je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
It was also of the opinion that, based on the experience of the use of pantoprazole, the availability of Pantoloc Control without medical supervision is appropriate. 
Menil je tudi, da je glede na izkušnje z uporabo pantoprazola dostopnost zdravila Pantoloc Control brez medicinskega nadzora ustrezna.
The recommended dose of Pantoloc Control is one tablet once a day until symptoms have stopped. 
Priporočeni odmerek zdravila Pantoloc Control je ena tableta enkrat na dan, dokler simptomi ne izzvenijo.
The European Commission granted a marketing authorisation valid throughout the EU for Pantoloc Control on 12 June 2009. 
Evropska komisija je dovoljenje za promet z zdravilom Pantoloc Control, veljavno po vsej Evropski uniji, odobrila dne 12. junija 2009.
The most common side effects with Pantoloc Control (seen in around 1 patient in 100) are diarrhoea and headache. 
Najpogostejša neželena učinka zdravila Pantoloc Control (opažena pri približno 1 bolniku od 100) sta driska in glavobol.
This is a summary of the European public assessment report (EPAR) for Pantoloc Control. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Pantoloc Control.
Pantoloc Control is similar to a ‘reference medicine' already authorised in the European Union (EU) called Pantoloc. 
Zdravilo Pantoloc Control je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Pantoloc.
For more information about treatment with Pantoloc Control, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Pantoloc Control preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Pantoloc Control must not be used in people who are hypersensitive (allergic) to pantoprazole, soya or any of the other ingredients. 
Zdravila Pantoloc Control ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) pantoprazol, sojo ali katero koli drugo sestavino zdravila.
It is used for long-term treatments and is also used to treat a wider range of gastrointestinal diseases (conditions affecting the gut) than Pantoloc Control. 
Uporablja se za dolgotrajno zdravljenje in za zdravljenje širšega spektra bolezni prebavil (stanj, ki prizadenejo črevesje) kot zdravilo Pantoloc Control.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pantoloc Control. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Pantoloc Control, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The CHMP therefore decided that Pantoloc Control's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Zato je zaključil, da so koristi zdravila Pantoloc Control večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Pantoloc Control is used for the short-term treatment of the symptoms of acid reflux in adults. 
Zdravilo Pantoloc Control se uporablja za kratkotrajno zdravljenje simptomov kislega refluksa pri odraslih.
What benefit has Pantoloc Control shown during the studies? 
Kakšne koristi je zdravilo Pantoloc Control izkazalo med študijami?
It must not be used with atazanavir (a medicine used to treat human immunodeficiency virus [HIV] infection). 
Zdravilo Pantoloc Control se ne uporabljati z atazanavirjem (zdravilom za zdravljenje okužbe z virusom človeške imunske pomanjkljivosti [HIV]).
Pantoloc Control is a medicine that contains the active substance pantoprazole. 
Zdravilo Pantoloc Control je zdravilo, ki vsebuje zdravilno učinkovino pantoprazol.
For the full list of all side effects reported with Pantoloc Control, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi pantoprazola, glejte navodilo za uporabo.
The active substance in Pantoloc Control, pantoprazole, is a proton pump inhibitor. 
Zdravilna učinkovina zdravila Pantoloc Control, pantoprazol, je zaviralec protonske črpalke.
The reference medicine, Pantoloc, is only available with a prescription. 
Referenčno zdravilo Pantoloc se izdaja le na recept.
Other information about Pantoloc Control 
Druge informacije o zdravilu Pantoloc Control:
What is the risk associated with Pantoloc Control? 
Kakšna tveganja so povezana z zdravilom Pantoloc Control?
Why has Pantoloc Control been approved? 
Zakaj je bilo zdravilo Pantoloc Control odobreno?
What is Pantoloc Control? 
Kaj je zdravilo Pantoloc Control?
What is Pantoloc Control used for? 
Za kaj se zdravilo Pantoloc Control uporablja?
How has Pantoloc Control been studied? 
Kako je bilo zdravilo Pantoloc Control raziskano?
How is Pantoloc Control used? 
Kako se zdravilo Pantoloc Control uporablja?
How does Pantoloc Control work? 
Kako zdravilo Pantoloc Control deluje?
The reference Member State was France and 12 concerned Member States were involved: Austria, Belgium, Denmark, Germany, Greece, Ireland, Italy, Luxembourg, Portugal, Slovenia, Spain and United Kingdom. 
Referenčna država članica je bila Francija, vključenih pa je bilo še 12 zadevnih držav članic: Avstrija, Belgija, Danska, Nemčija, Grčija, Irska, Italija, Luksemburg, Portugalska, Slovenija, Španija in Združeno kraljestvo.
The type II variation procedure (FR/V/0201/002/II/006) started on 16 May 2012. 
Postopek za spremembo tipa II (FR/V/0201/002/II/006) se je začel 16. maja 2012.
The final opinion was converted into a Decision by the European Commission on 25 September 2013. 
Končno mnenje je bilo 25. septembra 2013 spremenjeno v sklep Evropske komisije.
The Committee appointed Dr B. Urbain as rapporteur and Dr M. Holzhauser-Alberti as co-rapporteur. 
Odbor je imenoval dr. B. Urbaina za poročevalca in dr. M. Holzhauser-Albertija za soporočevalca.
Article 13 of Commission Regulation (EC) No. 1234/2008 
Člen 13 Uredbe Komisije (ES) št. 1234/2008.
On Day 90, major issues raised by the CMS, Belgium, remained unsolved. 
Na 90. dan so bila pomembna vprašanja, ki jih je sprožila zadevna država članica Belgija, še vedno nerešena.
On 3 April 2013, France referred the matter to the CVMP under Article 13(2) of Commission Regulation (EC) No 1234/2008. 
3. aprila 2013 je Francija zadevo napotila na CVMP v skladu s členom 13(2) Uredbe Komisije (ES) št. 1234/2008.
The referral procedure started on 10 April 2013. 
Napotitveni postopek se je začel 10. aprila 2013.
International non-proprietary names (INN): moxidectin and triclabendazole 
Mednarodna nelastniška imena (INN): moksidektin in triklabendazol
Written explanations were provided by the marketing authorisation holder on 20 May 2013. 
Imetnik dovoljenja za promet z zdravilom je 20. maja 2013 predložil pisna pojasnila.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II together with the amendments of the relevant sections of the Summary of Product Characteristics, labelling and package leaflet in Annex III. 
Seznam zadevnih imen zdravila je v Prilogi I. Znanstveni zaključki so podani v Prilogi II, skupaj s spremembami zadevnih poglavij povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo v Prilogi III.
During the variation procedure a potential serious risk to animal health was identified by Belgium and in particular that the efficacy against the lice species had been insufficiently substantiated. 
Med postopkom je Belgija opozorila na možno resno tveganje za zdravje živali in predvsem na dejstvo, da učinkovitost proti ušem ni zadovoljivo podprta z dokazi.
The CVMP concluded that a satisfactory efficacy towards Linognatus vituli, Bovicola bovis and Solenopotes capillatus can be expected in the field. 
CVMP je zaključil, da je v praksi mogoče pričakovati zadovoljivo učinkovitost proti vrstam Linognatus vituli, Bovicola bovis in Solenopotes capillatus.
The CVMP was requested to give its opinion on whether or not the data for the type II variation application support the new indication against lice infestations. 
CVMP so zaprosili za mnenje o tem, ali podatki za vlogo za spremembo tipa II podpirajo novo indikacijo proti infestacijam z ušmi.
The product is administered topically on the back of the animal and is indicated for the treatment of mixed nematode and fluke infections in cattle. 
Zdravilo se nanaša lokalno na hrbet živali in je indicirano za zdravljenje mešanih okužb z glistami in metljaji pri govedu.
Day 60 of the CMD(v) procedure was on 14 March 2013, and since there was no agreement the procedure was referred to the CVMP. 
Ker na 60. dan postopka skupine CMD(v), 14. marca 2013, ni bilo doseženo soglasje, je bil postopek napoten na CVMP.
The CMD(v) 60-day referral procedure was initiated on 14 January 2013. 
60-dnevni napotitveni postopek se je začel 14. januarja 2013.
The marketing authorisation holder, Pfizer Animal Health, submitted an application for a type II variation, according to Article 16 of Commission Regulation (EC) 1234/2008, to add a new indication against lice species (Linognatus vituli, Bovicola bovis and Solenopotes capillatus) for Cydectin TriclaMox 5 mg/ml and 200 mg/ml pour-on solution for cattle. 
Imetnik dovoljenja za promet z zdravilom, družba Pfizer Animal Health, je predložil vlogo za spremembo tipa II v skladu s členom 16 Uredbe Komisije (ES) 1234/2008 za vključitev nove indikacije proti ušem (Linognatus vituli, Bovicola bovis in Solenopotes capillatus) za zdravilo Cydectin TriclaMox 5 mg/ml in 200 mg/ml raztopina za kožni poliv za govedo.
Based on the evaluation of the available data, the CVMP adopted, on 16 July 2013, an opinion recommending the granting of the variation to the marketing authorisations for Cydectin TriclaMox (5 mg/ml and 200 mg/ml) pour-on solution for cattle. 
Na podlagi ocene razpoložljivih podatkov je CVMP dne 16. julija 2013 sprejel mnenje, s katerim je priporočil odobritev spremembe dovoljenj za promet z zdravilom Cydectin TriclaMox (5 mg/ml in 200 mg/ml) raztopina za kožni poliv za govedo.
Cydectin TriclaMox (5 mg/ml and 200 mg/ml) pour-on solution for cattle is a veterinary medicinal product containing 5 mg moxidectin per ml and 200 mg triclabendazole per ml. 
Cydectin TriclaMox (5 mg/ml in 200 mg/ml) raztopina za kožni poliv za govedo je zdravilo za uporabo v veterinarski medicini, ki vsebuje 5 mg moksidektina na ml in 200 mg triklabendazola na ml.
The procedure was thus referred to the Co-ordination Group for Mutual Recognition and Decentralised Procedures-Veterinary (CMD(v)) under Article 13(1) of Commission Regulation (EC) No 1234/2008 on 11 December 2012 by the RMS (France). 
Zato je 11. decembra 2012 referenčna država članica (Francija) postopek napotila na Usklajevalno skupino za postopek z medsebojnim priznavanjem in decentralizirani postopek - zdravila za uporabo v veterinarski medicini (CMD(v)) v skladu s členom 13(1) Uredbe Komisije (ES) št.
Opinion following an Article 131 referral for Cydectin TriclaMox (5 mg/ml and 200 mg/ml) pour-on solution for cattle 
za zdravilo Cydectin TriclaMox (5 mg/ml in 200 mg/ml) raztopina za kožni poliv za govedo
The differences were not statistically significant. 
Razlike niso bile statistično značilne.
This could be dangerous to yourself or others. 
Pri tem lahko ogrozite sebe ali druge.
Date of first authorisation: 18 September 2014 Date of latest renewal: 08 July 2019 
Datum prve odobritve: 18. september 2014 Datum zadnjega podaljšanja: 8. julij 2019
The recommended starting dose should not be exceeded. 
Priporočenega začetnega odmerka se ne sme prekoračiti.
How much solution is left? 
Koliko raztopine je še preostalo?
Choose a time of the day that works best for you. 
Izberite čas dneva, ki vam najbolj ustreza.
This is especially important if you take more than one type of injectable medicine. 
To je še posebej pomembno, če uporabljate več kot le eno zdravilo za injiciranje.
One study was further extended to 52 weeks. 
Eno študijo so podaljšali na 52 tednov.
The relevance for humans is likely to be low but cannot be completely excluded. 
Pomen tega za človeka je verjetno majhen, vendar pa ga ni mogoče povsem izključiti.
These may be signs of a very serious condition called ‘ketoacidosis'. 
To so lahko znaki zelo resnega stanja, ki ga imenujemo “ketoacidoza”.
Do not give this medicine to children or adolescents. 
Tega zdravila ne dajajte otrokom ali mladostnikom.
Before opening 
Pred prvim odprtjem
• not give you any food or drink - because you may choke. 
• ne smejo pa vam dajati hrane ali pijače, saj se lahko zadušite.
CI: 95% confidence interval. 
95 % interval zaupanja.
GLP-1 is a physiological regulator of appetite and food intake, but the exact mechanism of action is not entirely clear. 
GLP-1 je fiziološki regulator apetita in vnosa hrane, vendar pa natančen mehanizem delovanja ni v celoti znan.
Local tolerance was assessed in rabbits and pigs. 
Lokalno toleranco so vrednotili pri kuncih in prašičih.
4.5 Interaction with other medicinal products and other forms of interaction 
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Farmakodinamične interakcije
• how to adjust the dose. 
• kako prilagoditi odmerek.
2 Check the flow 
2 Preverite pretok
ATC code: A10AE56 
Oznaka ATC: A10AE56.
• how much Xultophy you will need each day 
• koliko zdravila Xultophy boste uporabili vsak dan,
Do not cover it with your fingers. 
Ne dotikajte se ga s prsti,
These tumours were not seen in monkeys treated for 20 months. 
Teh tumorjev niso opazili pri opicah, ki so jih zdravili 20 mesecev.
• a reminder of the need to report all medication errors irrespective of whether or not they resulted in an adverse event. 
• opomnik, da je treba poročati o vseh napakah, povezanih z uporabo zdravila, ne glede na to, če se je posledično pojavil neželeni učinek ali ne.
The MAH shall agree the final content and modality of distribution for the educational materials together with a communication plan, with the National Competent Authority in each Member State prior to distribution of the educational materials in the Member State. 
Imetnik dovoljenja za promet bo končno besedilo in način distribucije izobraževalnega gradiva ter načrt komuniciranja v državi članici uskladil v dogovoru s pristojnim nacionalnim organom v vsaki državi članici pred distribucijo izobraževalnega gradiva.
The duration of observation was minimum 3.5 years and up to a maximum of 5 years. 
3,5 leta in do največ 5 let.
These reactions were usually mild and transitory and they normally disappear during continued treatment. 
Te reakcije so bile običajno blage in prehodne, med nadaljevanjem zdravljenja pa so običajno izzvenele.
Tell your doctor if you are pregnant, think you might be pregnant or are planning to have a baby. 
Obvestite zdravnika, če ste noseči, menite, da bi lahko bili noseči ali načrtujete zanositev.
You should therefore monitor your blood sugar level more often than usual. 
Koncentracijo krvnega sladkorja morate zato kontrolirati bolj pogosto kot običajno.
What others need to do if you pass out: 
Kaj morajo storiti drugi, če se onesvestite
Time since Randomisation (Week) 
Čas od randomizacije (teden)
Use in elderly patients (65 years old or over) 
Uporaba pri starejših bolnikih (starih 65 let ali starejših)
The efficacy and safety of Xultophy were sustained up to 52 weeks of treatment. 
Učinkovitost in varnost zdravila Xultophy sta se ohranili do 52. tedna zdravljenja.
The educational materials should contain: - Summary of product characteristics and package leaflet; - Healthcare professional brochure that should contain the following key elements: 
Izobraževalno gradivo mora vsebovati: - povzetek glavnih značilnosti zdravila in navodilo za uporabo, - brošuro za zdravstvene delavce, ki bo vsebovala naslednje ključne navedbe:
A minimum of 8 hours between injections should always be ensured. 
Zagotoviti je treba, da med posameznima injiciranjima vedno mine najmanj 8 ur.
No interaction study has been performed. 
Študije medsebojnega delovanja niso izvedli.
The proportion of patients reporting nausea per week at any point during treatment was below 4%. 
Delež bolnikov, ki so poročali o navzei, je bil manjši od 4 % v vsakem tednu zdravljenja.
This is usually only short-lasting. 
To običajno kmalu mine.
This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using machines). 
To lahko predstavlja tveganje pri dejavnostih, pri katerih so takšne sposobnosti še posebej pomembne (npr.
• you have had low blood sugar a few times recently. 
• ste pred kratkim imeli večkrat prenizek krvni sladkor.
Change the needle as described in section 5 and repeat all steps starting with section 1: Prepare your pen with a new needle. 
Zamenjajte iglo, kot je opisano pod točko 5, in ponovite vse korake, začenši s točko 1, “Pripravite injekcijski peresnik z novo injekcijsko iglo”.
Taking the wrong medicine could be harmful to your health. 
Z uporabo napačnega zdravila lahko ogrozite svoje zdravje.
• have eye problems. 
• če imate težave z očmi.
Pay special attention to these notes as they are important for safe use of the pen. 
Upoštevajte te opombe, ker so pomembne za varno uporabo injekcijskega peresnika.
Dose counter stopped: 42 dose steps left 
števec odmerka se je ustavil: preostalo je še 42 odmernih korakov
After first opening: Use within 21 days 
Po prvem odprtju: porabite v 21 dneh.
• if you are allergic to insulin degludec or liraglutide or any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični na insulin degludek, liraglutid ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
It is therefore recommended that the patient always carries sugar-containing products 
Priporočljivo je, da ima bolnik vedno pri sebi živila, ki vsebujejo sladkor.
No data is available beyond 52 weeks of treatment. 
Podatki o zdravljenju, daljšem od 52 tednov, niso na voljo.
Detailed instructions for use are on the other side of this leaflet. 
Podrobna navodila za uporabo so na voljo na drugi strani tega navodila.
For study results with respect to combinations, effects on glycaemic control, and the populations studied, see sections 4.4, 4.5 and 5.1. 
Za rezultate študij v zvezi s kombinacijami, učinki na urejenost glikemije in skupinami bolnikov, ki so jih preučili, glejte poglavja 4.4., 4.5 in 5.1.
Two minor plasma metabolites were detected (≤9% and ≤5% of total plasma radioactivity exposure). 
Odkrili so tudi dva manj pomembna presnovka v plazmi (≤ 9 % in ≤ 5 % celotne izpostavljenosti plazme radioaktivnosti).
Tell them what could happen if your blood sugar gets low, including the risk of passing out. 
Povejte jim kaj se lahko zgodi v primeru prenizkega krvnega sladkorja, vključno s tveganjem, da se onesvestite.
The Xultophy clinical development programme included approximately 1,900 patients treated with Xultophy. 
V klinični razvojni program zdravila Xultophy je bilo vključenih približno 1.900 bolnikov, ki so se zdravili z zdravilom Xultophy.
If no drop appears, repeat steps 2A to 2C up to 6 times. 
Če se kapljica ne pojavi, ponovite korake od 2A do 2C, vendar pa ne več kot 6-krat.
• other medicines for diabetes (tablets or injections) 
• druga zdravila za zdravljenje sladkorne bolezni (tablete ali injekcije),
Name and address of the manufacturer of the biological active substances Novo Nordisk A/S 
Ime in naslov izdelovalcev biološke učinkovine Novo Nordisk A/S
• drink alcohol 
• uživate alkohol,
After first opening, the medicinal product can be stored for 21 days at a maximum temperature of 30°C. 
2 leti Po prvem odprtju se zdravilo lahko shranjuje 21 dni pri temperaturi do 30 °C.
• Serious allergic reaction (anaphylactic reaction) (not known: frequency cannot be estimated from the available data). 
• resna alergijska reakcija (anafilaktična reakcija) (pogostnost neznana - pogostnosti iz razpoložljivih podatkov ni mogoče oceniti)